Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $39.2200 (-2.63%) ($39.2200 - $39.2200) on Mon. Jul. 12, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.9% (three month average) | RSI | 57 | Latest Price | $39.2200(-2.63%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.5% a day on average for past five trading days. | Weekly Trend | TGTX advances 0.7% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(68%) ARKG(63%) ARKK(59%) IBB(59%) IWO(59%) | Factors Impacting TGTX price | TGTX will decline at least -1.45% in a week (0% probabilities). VIXM(-46%) VXX(-38%) UUP(-19%) UNG(-3%) TLT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.45% (StdDev 2.9%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $38.92(0.77%) | 10 Day Moving Average | $39.12(0.26%) | 20 Day Moving Average | $38.57(1.69%) | To recent high | -14.6% | To recent low | 20.9% | Market Cap | $4.967b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |